Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€118.20

€118.20

0.510%
0.6
0.510%
€124.92
 
19.04.24 / Tradegate WKN: A0YD8Q / Symbol: MRK / Name: Merck & Co / Stock / Pharmaceuticals / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Merck & Co. Inc. Stock

Merck & Co. Inc. gained 0.510% compared to yesterday.
The stock is one of the favorites of our community with 27 Buy predictions and 1 Sell predictions.
As a result the target price of 124 € shows a slightly positive potential of 4.91% compared to the current price of 118.2 € for Merck & Co. Inc..
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Merck & Co. Inc. stock. Negative votes have not been in the majority for any criteria for this stock

Pros and Cons of Merck & Co. Inc. in the next few years

Pros
?
S********** s********
?
B****
?
W********* I********* f** t** n*** y****
Cons
?
M***** P*******
?
G***** c******* t* c**********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Merck & Co. Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Merck & Co. Inc. 0.510% 0.000% 5.160% 13.436% 20.000% 83.227% 81.233%
Pfizer Inc. 2.180% 0.308% -4.165% -33.633% -6.552% -24.606% -26.614%
Elanco Animal Health Inc. -6.370% -9.960% -15.859% 40.625% -10.133% -51.439% -
Biogen Inc. 0.700% -2.066% -9.384% -31.597% -22.604% -18.381% -9.452%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-04-16

The financial statements of Merck & Co, a prominent player in the pharmaceutical industry, reflect a company that is performing relatively well in terms of operational efficiency, profitability, and growth. Although Merck faces risks, common to pharmaceutical companies, including R&D expenses, regulatory compliance, and competition, the company appears to be maintaining stable growth over the past years. The following analysis discusses both the positives and negatives associated with the company's financials.

*Pros: *

Revenue Growth: Merck's total revenue has grown consistently over the past three years, indicating a successful expansion and growth strategy. This points to a strong product pipeline and competent market positioning, which are essential factors for success in the pharmaceutical industry.

Comments

Prediction Buy
Perf. (%) 0.17%
Target price 131.946
Change
Ends at 08.04.25

Merck & Co., Inc. (NYSE: MRK) had its price target raised by analysts at Berenberg Bank from $140.00 to $143.00. They now have a "buy" rating on the stock.
Ratings data for MRK provided by MarketBeat
Show more

Prediction Buy
Perf. (%) 0.34%
Target price 124.767
Change
Ends at 05.04.25

Merck & Co., Inc. (NYSE: MRK) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $135.00 price target on the stock.
Ratings data for MRK provided by MarketBeat
Show more

Prediction Buy
Perf. (%) -3.11%
Target price 131.407
Change
Ends at 28.03.25

Merck & Co., Inc. (NYSE: MRK) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $142.00 price target on the stock, up previously from $139.00.
Ratings data for MRK provided by MarketBeat
Show more